Skeletal muscle loss is an independent negative prognostic factor in patients with advanced lower rectal cancer treated with neoadjuvant chemoradiotherapy

Backgrounds: The relationship between sarcopenia, characterized by loss of muscle mass and strength, and survival outcomes of esophageal cancer is controversial. This study aimed to assess the effect of sarcopenia and skeletal muscle loss on overall survival (OS) and recurrence-free survival (RFS) of esophageal cancer patients. Methods: We retrospectively collected the medical records of 248 male patients diagnosed with squamous cell esophageal cancer and who underwent neoadjuvant chemoradiotherapy (NACRT) followed by surgery. We measured the cross-sectional area of the skeletal muscle at the L3 vertebra level using computed tomography images and calculated the skeletal muscle index (SMI). Sarcopenia was defined as SMI <52.4 cm2/m2, and excessive muscle loss was defined as SMI change <−10.0%/50 days during NACRT. Moreover, laboratory test results, such as albumin, prognostic nutritional index (PNI), neutrophil-to-lymphocyte ratio (NLR), and platelet-to-lymphocyte ratio (PLR) before and after NACRT, were collected. Results: In the univariable Cox analysis, pre- (p = 0.689) and post-radiotherapy (RT) sarcopenia (p = 0.669) were not associated with OS. However, excessive muscle loss had a significant association with OS in both the univariable and multivariable analyses (all p = 0.001). Excessive muscle loss was also related to RFS in both the univariable (p = 0.011) and multivariable (p = 0.022) Cox analysis. Patients with excessive muscle loss had significantly lower levels of post-RT albumin (p < 0.001) and PNI (p < 0.001), higher levels of post-RT NLR (p = 0.031) and PLR (p = 0.071), larger decrease in albumin (p < 0.001) and PNI (p < 0.001) after NACRT, and larger increase in NLR (p = 0.051) and PLR (p = 0.088) after NACRT than in those with non-excessive muscle loss. Conclusion: Excessive muscle loss rather than pre- and post-RT sarcopenia was a significant prognostic factor for OS and RFS, and it was also related to nutritional and inflammatory markers.

Download Full-text

High plasma fibrinogen level represents an independent negative prognostic factor regarding cancer-specific, metastasis-free, as well as overall survival in a European cohort of non-metastatic renal cell carcinoma patients

British Journal of Cancer ◽

10.1038/bjc.2013.443 ◽

2013 ◽

Vol 109 (5) ◽

pp. 1123-1129 ◽

Cited By ~ 66

Author(s):

M Pichler ◽

G C Hutterer ◽

T Stojakovic ◽

S Mannweiler ◽

K Pummer ◽

...

Keyword(s):

Renal Cell Carcinoma ◽

Overall Survival ◽

Prognostic Factor ◽

Cell Carcinoma ◽

Renal Cell ◽

Fibrinogen Level ◽

High Plasma ◽

Plasma Fibrinogen Level ◽

Negative Prognostic Factor ◽

Independent Negative Prognostic Factor

Download Full-text

Time course of skeletal muscle loss and oxidative stress in rats with walker 256 solid tumor

Muscle & Nerve ◽

10.1002/mus.21798 ◽

2010 ◽

Vol 42 (6) ◽

pp. 950-958 ◽

Cited By ~ 38

Author(s):

Flávia A. Guarnier ◽

Alessandra L. Cecchini ◽

Andréia A. Suzukawa ◽

Ana Leticia G.C. Maragno ◽

Andréa N.C. Simão ◽

...

Keyword(s):

Oxidative Stress ◽

Skeletal Muscle ◽

Solid Tumor ◽

Time Course ◽

Muscle Loss ◽

Skeletal Muscle Loss ◽

Walker 256 ◽

And Oxidative Stress

Download Full-text

Elevated CA19-9 as the Most Significant Prognostic Factor in Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiotherapy

Medicine ◽

10.1097/md.0000000000001793 ◽

2015 ◽

Vol 94 (45) ◽

pp. e1793 ◽

Cited By ~ 6

Author(s):

Lu-Ning Zhang ◽

Pu-Yun OuYang ◽

Wei-Wei Xiao ◽

Xin Yu ◽

Kai-Yun You ◽

...

Keyword(s):

Rectal Cancer ◽

Prognostic Factor ◽

Locally Advanced ◽

Neoadjuvant Chemoradiotherapy ◽

Advanced Rectal Cancer ◽

Locally Advanced Rectal Cancer ◽

Significant Prognostic Factor

Download Full-text

Circulating Tumor Cells Counting Act as a Potential Prognostic Factor in Cervical Cancer

Technology in Cancer Research & Treatment ◽

10.1177/1533033820957005 ◽

2020 ◽

Vol 19 ◽

pp. 153303382095700 ◽

Cited By ~ 1

Author(s):

Kunpeng Du ◽

Qian Huang ◽

Junguo Bu ◽

Jieling Zhou ◽

Zijian Huang ◽

...

Keyword(s):

Cervical Cancer ◽

Prognostic Factor ◽

Progression Free Survival ◽

Disease Stage ◽

Histological Differentiation ◽

Free Survival ◽

Pathological Type ◽

Negative Prognostic Factor ◽

The Relationship ◽

Independent Negative Prognostic Factor

Background: Circulating tumor cells (CTCs) hold huge potential for both clinical applications and basic research into the management of cancer, but the relationship between CTC count and cervical cancer prognosis remains unclear. Therefore, research on this topic is urgently required. Objective: This study investigated whether CTCs were detectable in patients with cervical cancer and whether CTC count was an indicator of prognosis. Methods: We enrolled 107 patients with pathologically confirmed cervical cancer. CTCs were detected after radiotherapy or concurrent cisplatin-containing chemotherapy in all patients. We evaluated all medical records and imaging data as well as follow-up information to calculate progression-free survival (PFS). PFS was defined as the time until first diagnosis of tumor progression or death. We also analyzed the relationship between CTC count and patient age, disease stage, histological differentiation, tumor size, and pathological type. Results: CTCs were identified in 86 of 107 patients (80%), and the CTC count ranged from 0 to 27 cells in 3.2 mL blood. The median progression-free survival (PFS) was 43.1 months. Patients in which CTCs were detected had a significantly shorter PFS than CTC-negative patients (P = 0.018). Multivariate analysis indicated that CTC count was an independent negative prognostic factor for survival. However, no correlation was observed between CTC count and patient age, disease stage, histological differentiation, tumor size, and pathological type. Conclusion: CTC count is an independent negative prognostic factor for cervical cancer.

Download Full-text